Results 81 to 90 of about 3,776 (143)

Rationale and Design of the Cancer Immunotherapy Evidence Living (CIEL) Library: A Continuously Updated Clinical Trial Database of Cancer Immunotherapies

Health Science Reports, Volume 9, Issue 4, April 2026.
ABSTRACT Background and Aims Immunotherapies for cancers are tested in large numbers of clinical trials. It is difficult for clinicians and researchers to stay current with the evidence, and traditional systematic reviews and clinical guidelines are not suited to ensure a continued overview of all trials and their results.
Kim Boesen, Julian Hirt, Pascal Düblin, Heinz Läubli, Benjamin Kassenda, Lars G. Hemkens, Perrine Janiaud   +6 more
wiley   +1 more source

Oncolytic viruses on the cusp of success?: proceedings of the 9th International Conference on Oncolytic Virus Therapeutics

Molecular Therapy: Oncolytics, 2016
Boston, Massachusetts, was the site of the 9th International Conference on Oncolytic Virus Therapeutics held 13–16 June 2015. An overarching theme of the meeting was the continued development of combinatorial treatment regimens to bolster the therapeutic
Cole Peters, Fares Nigim, E Antonio Chiocca, Samuel D Rabkin   +3 more
doaj   +1 more source

Oncolytic Therapy: Delivery System and New Therapeutic Strategies for Cancer

MedComm, Volume 7, Issue 4, April 2026.
This review summarizes recent advances in nanoparticle‐ and cell‐mediated OVs delivery strategies that improve biodistribution and tumor targeting while limiting immune clearance. It also examines combination approaches that enhance therapeutic efficacy through tumor microenvironment modulation or immune activation, thereby overcoming immunosuppression
Sikan Jin, Yi Zhang, Ziling Zhou, Yaqi Zhang, Ting Yu, Rui Xu, Lin Xu, Jidong Zhang, Longze Zhang, Shan Yang, Xianyao Wang   +10 more
wiley   +1 more source

Additional file 1: of Final analyses of OPTiM: a randomized phase III trial of talimogene laherparepvec versus granulocyte-macrophage colony-stimulating factor in unresectable stage III–IV melanoma

, 2019
Supplement to: Final analyses of OPTiM: a randomized phase III trial of talimogene laherparepvec versus granulocyte-macrophage colony-stimulating factor in unresectable stage III–IV melanoma (DOC 154 ...
Kevin Harrington (371839), Gerald Downey (817275), Howard Kaufman (3526127), Frances Collichio (6808961), Mark Middleton (3746080), Robert Andtbacka (6808958), Katarina ÓŚhrling (6808967)   +6 more
core   +1 more source

Complete intracranial response to talimogene laherparepvec (T-Vec), pembrolizumab and whole brain radiotherapy in a patient with melanoma brain metastases refractory to dual checkpoint-inhibition

Journal for ImmunoTherapy of Cancer, 2018
Background Immunotherapy, in particular checkpoint blockade, has changed the clinical landscape of metastatic melanoma. Nonetheless, the majority of patients will either be primary refractory or progress over follow up. Management of patients progressing
Zoë Blake, Douglas K. Marks, Robyn D. Gartrell, Thomas Hart, Patti Horton, Simon K. Cheng, Bret Taback, Basil A. Horst, Yvonne M. Saenger   +8 more
doaj   +1 more source

Prospects for combined use of oncolytic viruses and CAR T-cells

Journal for ImmunoTherapy of Cancer, 2017
With the approval of talimogene laherparepvec (T-VEC) for inoperable locally advanced or metastatic malignant melanoma in the USA and Europe, oncolytic virotherapy is now emerging as a viable therapeutic option for cancer patients. In parallel, following
Adam Ajina, John Maher
doaj   +1 more source

Oncolytic Herpes Simplex Virus Therapy: Latest Advances, Core Challenges, and Future Outlook

Vaccines
Oncolytic virus (OV) immunotherapy, particularly with oncolytic herpes simplex virus (oHSV), has become a promising new strategy in cancer treatment. This field has achieved significant clinical milestones, highlighted by the FDA approval of Talimogene ...
Yiyang Zheng, Yusheng Pei, Chunyan Dong, Jinghui Liang, Tong Cai, Yuan Zhang, Dejiang Tan, Junzhi Wang, Qing He   +8 more
doaj   +1 more source

Abstract OT1-01-05: A phase II study using talimogene laherparepvec as a single agent for inflammatory breast cancer or non-inflammatory breast cancer patients with inoperable local recurrence

, 2018
Objective: The primary purpose of the study is to determine the local and systemic antitumor efficacy of talimogene laherparepvec in locally recurrent breast cancer patients with or without distant metastases, as evidenced by improved overall response ...
GJ Whitman, B Lim, NT Ueno, NK Ibrahim, Y Shen, S Krishnamurthy, DD Liu, EA Mittendorf, A Lucci, WA Woodward, AN Marx, JM Reuben, JS Willey, HT Le-Petross, V Valero   +14 more
core   +1 more source

Virotherapy: cancer gene therapy at last? [version 1; referees: 2 approved]

F1000Research, 2016
For decades, effective cancer gene therapy has been a tantalising prospect; for a therapeutic modality potentially able to elicit highly effective and selective responses, definitive efficacy outcomes have often seemed out of reach.
Alan E. Bilsland, Pavlina Spiliopoulou, T. R. Jeffry Evans   +2 more
doaj   +1 more source

New frontiers in oncolytic viruses: optimizing and selecting for virus strains with improved efficacy

Biologics: Targets & Therapy, 2018
Kenneth Lundstrom PanTherapeutics, Lutry, Switzerland Abstract: Oncolytic viruses have demonstrated selective replication and killing of tumor cells.
Lundstrom K
doaj